Hillsdale Investment Management Inc. Acquires 1,700 Shares of Intuitive Surgical, Inc. $ISRG

Posted by Renee Jackson on Jul 16th, 2026

Hillsdale Investment Management Inc. increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) by 116.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,160 shares of the medical equipment provider’s stock after purchasing an additional 1,700 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Intuitive Surgical were worth $1,457,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC boosted its position in Intuitive Surgical by 24.9% during the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after acquiring an additional 731 shares during the last quarter. Sivia Capital Partners LLC raised its position in shares of Intuitive Surgical by 3.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock worth $504,000 after acquiring an additional 34 shares in the last quarter. Schnieders Capital Management LLC. lifted its stake in shares of Intuitive Surgical by 38.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock valued at $529,000 after purchasing an additional 268 shares during the period. Osterweis Capital Management Inc. bought a new stake in shares of Intuitive Surgical during the 2nd quarter valued at about $200,000. Finally, Main Street Financial Solutions LLC boosted its position in shares of Intuitive Surgical by 92.4% during the 2nd quarter. Main Street Financial Solutions LLC now owns 2,929 shares of the medical equipment provider’s stock valued at $1,592,000 after purchasing an additional 1,407 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

ISRG opened at $388.97 on Thursday. Intuitive Surgical, Inc. has a fifty-two week low of $378.50 and a fifty-two week high of $603.88. The firm has a market capitalization of $137.76 billion, a PE ratio of 47.15, a P/E/G ratio of 3.09 and a beta of 1.46. The company’s 50-day moving average is $418.39 and its 200 day moving average is $469.98.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last released its quarterly earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.42. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.62 billion. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The company’s quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.81 EPS. As a group, analysts expect that Intuitive Surgical, Inc. will post 8.57 EPS for the current year.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

Positive Sentiment: BMO Capital initiated coverage with an Outperform rating, adding to the case that Intuitive Surgical can continue to defend its leadership in robotic surgery. BMO Capital Starts Intuitive Surgical (ISRG) at Outperform
Positive Sentiment: Several articles note that ISRG heads into earnings with strong procedure momentum, da Vinci 5 adoption, and a history of beating estimates, which supports hopes for another solid quarter. Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now?
Positive Sentiment: Intuitive Surgical’s Ion lung biopsy study is approaching a data readout, highlighting a potential new growth avenue beyond core robotic surgery. Intuitive Surgical’s Ion Lung Biopsy Study Nears Data Readout, Eyeing New Growth in Diagnostics
Neutral Sentiment: Commentary around Intuitive Surgical’s leadership versus rising global competition is mixed: the company is using AI features and a broad ecosystem to defend share, but competition remains a watch item. Can ISRG Defend Its Leadership as Global Competition Intensifies?
Neutral Sentiment: Some coverage frames the move as a pre-earnings repositioning event, with investors weighing recent analyst target cuts, margin pressure from tariffs, and broader medical-device weakness more than any new company-specific setback. Intuitive Surgical Falls as Target Cut and Pre-Earnings Jitters Weigh on Shares

Insider Activity

In related news, Director Amy L. Ladd sold 500 shares of the stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $473.46, for a total value of $236,730.00. Following the completion of the sale, the director directly owned 239 shares of the company’s stock, valued at approximately $113,156.94. This represents a 67.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $420.55, for a total value of $2,365,593.75. Following the transaction, the senior vice president owned 6,463 shares in the company, valued at approximately $2,718,014.65. This trade represents a 46.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,169 shares of company stock worth $3,059,135 over the last 90 days. 0.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ISRG. Mizuho set a $500.00 price objective on shares of Intuitive Surgical and gave the stock a “neutral” rating in a research report on Wednesday. Truist Financial cut their target price on shares of Intuitive Surgical from $650.00 to $580.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. TD Cowen reduced their price target on shares of Intuitive Surgical from $585.00 to $520.00 and set a “buy” rating for the company in a report on Monday. Royal Bank Of Canada decreased their price target on shares of Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating for the company in a research note on Monday. Finally, Bank of America dropped their price objective on shares of Intuitive Surgical from $520.00 to $515.00 in a report on Friday, June 12th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $565.31.

View Our Latest Report on ISRG

About Intuitive Surgical

(Free Report)

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.